Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health‐related quality of life improvements and implications for treatment goals

2019 ◽  
Vol 182 (4) ◽  
pp. 965-973 ◽  
Author(s):  
J.M. Norlin ◽  
K. Nilsson ◽  
U. Persson ◽  
M. Schmitt‐Egenolf
Keyword(s):  
Quality Of Life ◽  
Clinical Practice ◽  
Response Rates ◽  
Severity Index ◽  
Treatment Goals ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life

2020 ◽  
Vol 31 (5) ◽  
pp. 470-475
Author(s):  
Sascha Gerdes ◽  
Andreas Körber ◽  
Mona Biermann ◽  
Claudia Karnthaler ◽  
Maximilian Reinhardt
Keyword(s):  
Quality Of Life ◽  
Severity Index ◽  
Treatment Goals ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

scholarly journals Health-Related Quality of Life Following Allogeneic Hematopoietic Stem Cell Transplantation

Hematology ◽  
2010 ◽  
Vol 2010 (1) ◽  
pp. 248-254 ◽  
Author(s):  
Margaret Bevans
Keyword(s):  
Quality Of Life ◽  
Stem Cell ◽  
Clinical Practice ◽  
Hematopoietic Stem Cell Transplantation ◽  
Health Related Quality ◽  
Hematopoietic Stem ◽  
Allogeneic Hsct ◽  
Related Quality ◽  
Health Related

Abstract It is common knowledge that an allogeneic hematopoietic stem cell transplantation (HSCT) will have an enormous impact on the lives of transplant recipients and their families. Once an appropriate donor is identified, the curative potential of this treatment often drives the decision to proceed knowing that there will be intense physiologic toxicities and adverse effects on health-related quality of life (HRQL). Twenty-five years ago, HRQL was identified as an efficacy parameter in the evaluation of new anticancer drug therapy. Overall, the evidence suggests that an allogeneic HSCT has a significant impact on the overall HRQL of recipients, which is a result of decrements across all dimensions, including a significant symptom profile. The degree of impact on overall HRQL and the multiple dimensions varies across the transplant trajectory. Specific HRQL dimensions, such as physical function and symptoms, are easily incorporated into a clinician's assessment whereas other dimensions (eg, psychosocial) are less commonly integrated. The translation of HRQL results to improve clinical practice is not well established. Clinicians are often uncertain when to assess the scope of HRQL and how to interpret the information in a clinically meaningful way. The purpose of this review is to highlight the quality-of-life effects of allogeneic HSCT and discuss application into clinical practice.

scholarly journals Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings

2020 ◽  
Vol 29 (10) ◽  
pp. 2651-2660
Author(s):  
Richard W. Joseph ◽  
Frank Xiaoqing Liu ◽  
Alicia C. Shillington ◽  
Cynthia P. Macahilig ◽  
Scott J. Diede ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Practice ◽  
Real World ◽  
Repeated Measures ◽  
Advanced Melanoma ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
Eq Vas

Abstract Background Pembrolizumab (PEMBRO) and ipilimumab + nivolumab (IPI + NIVO) are approved advanced melanoma (AM) immunotherapies. To address limited health-related quality of life (QoL) real-world evidence with immunotherapies in AM, we compared QoL in AM patients receiving either treatment in clinical practice. Methods A prospective US observational study enrolled adult AM patients initiating first-line PEMBRO or IPI + NIVO between June 2017 and March 2018. Endpoints included the QLQ-C30 global health score (GHS) and EuroQol visual analog scale (EQ-VAS) scores. Mean changes were compared using repeated measures mixed-effects models and are presented covariate adjusted. Results 225 PEMBRO and 187 IPI + NIVO patients were enrolled. From baseline through week 24, PEMBRO was associated with 3.2 mean GHS score increase (95% CI 0.5, 5.9; p = .02), while no change was observed with IPI + NIVO; 0.2 (95% CI − 2.6, 3.0; p = 0.87). Among objective treatment-responders, GHS scores associated with PEMBRO increased 6.0 (95% CI 3.1, 8.8; p < .0001); IPI + NIVO patients increased 3.8 (95% CI 0.8, 6.9; p = .01). In treatment non-responders, IPI + NIVO was associated with GHS/QoL deterioration of − 3.7 (95% CI − 6.8, − 0.6; p = .02), PEMBRO non-responders demonstrated no change; 0.7 (95% CI − 2.3, 3.7; p = 0.6). Between treatments, PEMBRO patients increased 2.6 greater in EQ-VAS (95% CI 0.6, 4.5; p = .01) vs IPI + NIVO at 24 weeks. Conclusions PEMBRO was associated with better 24-week QoL compared to IPI + NIVO in actual clinical practice settings. Real-world data has known limitations, but with further confirmation these results may have implications for treatment selection.

Single inhaler triple therapy in patients with COPD: response rates in health-related quality of life in the IMPACT Trial

2018 ◽  
Author(s):  
Maggie Tabberer ◽  
Christine Elaine Jones ◽  
Sally Kilbride ◽  
Gerard J Criner ◽  
Peter Lange ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Triple Therapy ◽  
Response Rates ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
The Impact
Sign in / Sign up

Export Citation Format

Share Document